NCHR Testimony at FDA on Approval of Abuse-Deterrent Opioid, Remoxy

June 26, 2018: To reduce the opioid epidemic, the FDA must hold pharmaceutical companies to a high and truthful standard. Remoxy did not meet the FDA’s standards for oral abuse, and it remains unclear whether it can be abused intravenously. The safety of the excipient is also in question. Please carefully consider the risks of putting another drug with abuse-deterrent labeling on the market that could result in misuse and abuse in the real world. We urge this Advisory Committee to vote that the benefits of this drug do not outweigh its risks.

Read More »

NCHR Testimony at FDA on ELEVAIR Endobronchial Coil System

Stephanie Fox-Rawlings, National Center for Health Research: June 14, 2018 Thank you for the opportunity to speak today on behalf of the National Center for Health Research. I am Dr. Stephanie Fox-Rawlings. Our Center analyzes scientific and medical data to provide objective health information to patients, health professionals, and policy makers. We do not accept […]

Read More »
Page 1 of 9812345...102030...Last »